Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [UMB5] to Somatostatin Receptor 3/SSTR3
- Suitable for: WB, Flow Cyt
- Reacts with: Human
Product nameAnti-Somatostatin Receptor 3/SSTR3 antibody [UMB5]
See all Somatostatin Receptor 3/SSTR3 primary antibodies
DescriptionRabbit monoclonal [UMB5] to Somatostatin Receptor 3/SSTR3
Tested applicationsSuitable for: WB, Flow Cytmore details
Unsuitable for: IHC-P or IP
Species reactivityReacts with: Human
Synthetic peptide within Human Somatostatin Receptor 3/SSTR3 aa 350-450 (C terminal). The exact sequence is proprietary.
- Somatostatin Receptor 3/SSTR3 transfected 293T cell lysate
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product was previously labelled as Somatostatin Receptor 3
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab137026 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/10000 - 1/50000. Predicted molecular weight: 46 kDa.|
|Flow Cyt||1/100 - 1/1000.
ab172730 - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.
FunctionReceptor for somatostatins-14 and -28. This receptor is coupled via pertussis toxin sensitive G proteins to inhibition of adenylyl cyclase.
Tissue specificityBrain, pituitary and pancreas.
Sequence similaritiesBelongs to the G-protein coupled receptor 1 family.
modificationsPhosphorylated. Phosphorylation increases upon somatostatin binding.
Cellular localizationCell membrane. Internalized into endoplasmic vesicles upon somatostatin-stimulation.
- Information by UniProt
- OTTHUMP00000028737 antibody
- Smstr 3 antibody
- Smstr3 antibody
Overlay histogram showing SHSY-5Y cells stained with ab137026 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab137026, 1/1000 dilution) for 30 min at 22°C. The secondary antibody used was Alexa Fluor® 488 goat anti-rabbit IgG (H&L) (ab150077) at 1/2000 dilution for 30 min at 22°C. Isotype control antibody (black line) was rabbit IgG (monoclonal) (0.1μg/1x106 cells) used under the same conditions. Unlabelled sample (blue line) was also used as a control. Acquisition of >5,000 events were collected using a 20mW Argon ion laser (488nm) and 525/30 bandpass filter. This antibody gave a positive signal in SHSY-5Y cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.
All lanes : Anti-Somatostatin Receptor 3/SSTR3 antibody [UMB5] (ab137026) at 1/10000 dilution
Lane 1 : Non-transfected 293T cell lysate
Lane 2 : Somatostatin Receptor 3/SSTR3 transfected 293T cell lysate
Lysates/proteins at 10 µg per lane.
All lanes : HRP labelled goat anti-rabbit at 1/2000 dilution
Predicted band size: 46 kDa
ab137026 has been referenced in 9 publications.
- Zou Y et al. Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells. Oncol Lett 17:1723-1731 (2019). PubMed: 30675231
- Storvall S et al. Somatostatin receptor expression in parathyroid neoplasms. Endocr Connect 8:1213-1223 (2019). PubMed: 31336364
- Venegas-Moreno E et al. Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly. J Cell Mol Med 22:1640-1649 (2018). IHC ; Human . PubMed: 29266696
- Kaemmerer D et al. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer 17:896 (2017). IHC-P ; Human . PubMed: 29282035
- Kaemmerer D et al. Evaluation of somatostatin, CXCR4 chemokine and endothelin A receptor expression in a large set of paragangliomas. Oncotarget 8:89958-89969 (2017). IHC-P ; Human . PubMed: 29163802
- Qian ZR et al. Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors. Pancreas 45:1386-1393 (2016). PubMed: 27622342
- Iacovazzo D et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol 174:241-50 (2016). PubMed: 26586796
- Norden AD et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology 84:280-6 (2015). PubMed: 25527270
- Peng Y et al. Comparative study of somatostatin-human serum albumin fusion proteins and natural somatostatin on receptor binding, internalization and activation. PLoS One 9:e89932 (2014). PubMed: 24587133